Search clinical trials for: Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ

Total 699 results

Novartis

Completed

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Essential Hypertension

Japan
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Novartis

Completed

Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine (AWESOME)

Essential Hypertension

Germany
Novartis

Completed

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Hypertension

Estonia, France, Iceland, India, Italy, Korea, Republic of, Lithuania, Spain, Venezuela
Vanderbilt University Medical Center

Completed

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

High Blood Pressure

United States
Novartis

Completed

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension (ASCENT)

Hypertension

United States
Novartis Pharmaceuticals

Terminated

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People (APOLLO)

Cardiovascular Events

Colombia, India, South Africa, Canada, Spain, Hungary, United States, Germany, Ireland, Argentina, Philippines, Brazil, Sweden, Malaysia, Chile, Israel, Czech Republic, Netherlands
Novartis Pharmaceuticals

Terminated

Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

Hypertension | Ankle Edema

Netherlands
Novartis

Completed

Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension (AMAZING)

Hypertension

Germany
Novartis Pharmaceuticals

Completed

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

Metabolic Syndrome | Insulin Resistance | Endothelial Dysfunction | High Blood Pressure

United States
Novartis

Completed

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

Hypertension

United States, Germany
Novartis

Completed

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

Hypertension

United States, Germany
Novartis

Terminated

Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension

Hypertension | Abdominal Obesity

Germany
Novartis

Completed

A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients. (ANDROMEDA)

High Blood Pressure

Venezuela
Novartis

Completed

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

Hypertension

Sweden, Slovakia, Argentina, Germany, Turkey, Norway, Poland
Novartis

Completed

Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension (ACADEMY)

Stage II Hypertension

Thailand
Novartis

Completed

Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension

Moderate to Severe Hypertension

Russian Federation, Romania, Singapore, Spain, Germany, Philippines
Novartis Pharmaceuticals

Completed

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans (ATLAAST)

Hypertension

United States
University of Pavia

Unknown

Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients

Hypertension

Italy
Novartis

Completed

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension (AACESS)

Hypertension

United States
Novartis

Completed

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

Hypertension

United States
Novartis

Completed

8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

Hypertension

United States
Novartis

Completed

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus (ASTRIDE)

Hypertension | Diabetes Mellitus

United States
Wayne State University
Novartis

Unknown

Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension (VDATH)

Hypertension

United States
Novartis

Completed

Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension (ACQUIRE)

Hypertension

Switzerland, Italy, Argentina, Germany, Turkey, United States, Ecuador, Guatemala
Novartis

Completed

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

Hypertension

India
Novartis

Completed

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Hypertension

Sweden, United States, Romania, Denmark, Israel, Italy, Germany, Australia, Canada, Latvia, Lithuania, Turkey
Novartis Pharmaceuticals

Terminated

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (ARIA)

Non-diabetic Nephropathy

Netherlands
John H. Stroger Hospital

Terminated

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

Diabetes | Proteinuria | Albuminuria | Microalbuminuria | Macroalbuminuric Diabetic Nephropathy

United States
Chinese University of Hong Kong

Completed

Aliskiren for Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

Hong Kong
Swiss Federal Institute of Sport Magglingen

Unknown

Comparison of the Automatized and the Optimized Carbon Monoxid Rebreathing Protocol

Hemoglobins

Switzerland
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension

Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical
Severance Hospital

Completed

Drug-drug Interaction Study(CKD-501, Amlodipine)

Type 2 Diabetes Mellitus

Korea, Republic of
Boehringer Ingelheim

Completed

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

Healthy

Japan
Novartis

Completed

A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.

Hypertension, Diabetes Mellitus

United States, Germany
Novartis

Completed

Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

Essential Hypertension

Switzerland, Germany
Brigham and Women's Hospital

Terminated

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

Insulin Sensitivity | Diastolic Function | Aortic Compliance

United States
Novartis

Completed

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

Hypertension

United States, Germany
Kagawa University

Unknown

A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

Hypertension | Glomerulonephritis, IGA

Japan
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan

Unknown

Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure

Congestive Heart Failure

Taiwan
Novartis

Completed

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients

Hypertension

United States, Germany
Novartis

Completed

Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy

Diabetes Type 2

Denmark
Novartis

Completed

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT)

Stage 2 Systolic Hypertension

United States
Texas Tech University Health Sciences Center

Completed

Direct Renin Inhibition Effects on Atherosclerotic Biomarkers

Coronary Artery Disease | Type 2 Diabetes Mellitus

United States
Novartis

Completed

Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.

Hypertension

Germany, United States
Novartis Pharmaceuticals

Completed

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

Heart Failure

Germany, Lithuania
Novartis

Completed

A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients

Hypertension | Diabetes

Switzerland, Sweden, Romania, Belgium, Spain, United States, Ukraine
Novartis

Completed

A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

Hypertension

United States
Novartis

Completed

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

Hypertension

United States, Belgium, Canada, Germany, Italy, Netherlands, Peru, Russian Federation, Switzerland, United Kingdom
Hospital Universitario Pedro Ernesto
Novartis

Withdrawn

Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan

Hypertension | Diabetes Mellitus

Brazil

3

Subscribe